Helena A. Yu

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Clinicogenomic analysis of <i>EGFR</i> -mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

  Science Translational Medicine · 2026-06-17

• Supplementary Table S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Figure S2 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Figure S3 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Clinical significance of <i>EGFR</i> amplification in patients with <i>EGFR</i> -mutated metastatic non–small cell lung cancer receiving first-line osimertinib.

  Journal of Clinical Oncology · 2026-05-28

• Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.

  Journal of Clinical Oncology · 2026-05-28

• Clinicogenomic determinants of early progression on first-line osimertinib in <i>EGFR</i> -mutant NSCLC.

  Journal of Clinical Oncology · 2026-05-28

• Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.

  Journal of Clinical Oncology · 2026-05-28

• Impact of genomic subtype on intracranial outcomes in treatment-naive <i>EGFR</i> -mutant NSCLC with osimertinib (IGnITE).

  Journal of Clinical Oncology · 2026-05-27

• Genomic correlates of leptomeningeal disease after brain metastasis resection.

  Journal of Clinical Oncology · 2026-05-27

• Cerebrospinal fluid biomarker profiling in patients with non–small cell lung cancer and leptomeningeal disease.

  Journal of Clinical Oncology · 2026-05-27

• Reply to: Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non–Small Cell Lung Cancer?

  Journal of Clinical Oncology · 2025-12-17

• Supplementary Methods, Tables, Figures from Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, &lt;i&gt;MET&lt;/i&gt;-Amplified Non–Small Cell Lung Cancer: TATTON

  2025-12-10

• Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Supplementary Figure S1 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S3 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplementary Table S6 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25

• Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Supplementary Table S5 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of &lt;i&gt;EGFR&lt;/i&gt;-Mutant and &lt;i&gt;RET&lt;/i&gt; Fusion-Positive Lung Cancers

  2025-11-25